Baseimmune
PrivateLast Round
Series A
Feb 26, 2024
Total Funding Raised
$17.15M
Company Overview
Baseimmune operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Series A round in February 2024.
Baseimmune is a biotechnology company that utilizes a proprietary deep learning AI platform to predict future pathogen mutations for the development of novel vaccines and immunotherapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Baseimmune Comparables
Compare Baseimmune with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Deepflare | 81% | |
| EVA Therapeutics, Inc. | 81% | |
| EVA Therapeutics, Inc. | 78% |
For institutional investors. Book with your work email.
Baseimmune Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Feb 26, 2024 | ||||
| Seed | Nov 2, 2021 | ||||
| Pre Seed | Apr 1, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Baseimmune Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Merck Global Health Innovation Fund | Series A |
| Beast Mode | Seed, Series A |
| Hoxton Ventures | Series A, Seed |
| IQ Capital | Series A |
| Rockmount Seed Investments | Seed, Pre Seed |
| Beast Ventures | Seed, Series A |
| Maki | Seed, Pre Seed, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 12, 2026
Unveiled a multi-pathway immunotherapy strategy for fibrosis.
- Feb 26, 2024
$11.4M round led by Merck Global Health Innovation Fund and IQ Capital.
For institutional investors. Book with your work email.
Baseimmune Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Baseimmune's valuation, stock price, and market status.
Is Baseimmune a public or private company?
Baseimmune is a private company.
What is the current stock price of Baseimmune?
Baseimmune is a private company, so its shares have no public market price. Caplight tracks Baseimmune's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Baseimmune worth (valuation)?
Valuation information for Baseimmune is not publicly available.
Can I buy Baseimmune stock?
Baseimmune shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Baseimmune's last funding round?
Baseimmune's most recent funding round was Series A on February 26, 2024.
Who are the main investors in Baseimmune?
Key investors in Baseimmune include Merck Global Health Innovation Fund, Hoxton Ventures, IQ Capital, The Creator Fund.
Will Baseimmune IPO soon?
No public IPO plans have been announced for Baseimmune.
How can I track Baseimmune secondary market activity?
Caplight tracks bids, offers, and trades in Baseimmune's shares on secondary markets.